April 29 () - Pfizer said on Wednesday its drug Elrexfio met the main goal in a late-stage trial that tested the blood ...
The FDA announced efforts to make clinical trials more efficient, starting by reviewing data in real time from trials ...
April 28 (Reuters) - Pfizer said on Tuesday it has settled patent disputes with three generic drugmakers over its blockbuster ...
Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...
Morning Overview on MSN
Pfizer settles patent fights, keeping heart drug shielded from generics to 2031
Patients taking Pfizer’s Vyndaqel and Vyndamax for a progressive, often fatal form of heart failure will not see cheaper ...
Through two pioneering studies, Amgen and AstraZeneca will share study data with FDA scientists as it’s accrued. Elsewhere, ...
Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have ...
Add Yahoo as a preferred source to see more of our stories on Google. The FDA has approved a label change to Pfizer's contraceptive injection The US Food and Drug Administration (FDA) has approved a ...
U.S. Food and Drug Administration "enforcement in the social media space has historically been somewhat limited, but recent activity suggests that the FDA is taking a closer look at how pharmaceutical ...
If the crackdown on pharma’s TV ads and subsequent extension to social media has underscored anything, it’s that brands need ...
As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, ...
Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results